Managers / Q4 2021 · view latest →
Gates Foundation
CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100
Summary
Gates Foundation reported $330M in U.S.-listed holdings across 11 positions for Q4 2021.
The portfolio is heavily concentrated: Curevac N V alone accounts for 32.6% of reported value.
Compared with Q3 2021, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 47.7% · $157M
- ADR · 38.1% · $126M
- Common Stock · 14.2% · $47M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| EXSCIENTIA | NEW | +1.59M | 1.59M | +$31M | $31M |
| CUREVAC N V | HELD | +0 | 3.13M | −$64M | $108M |
| IMCRIMMUNCORE HLDGS PLC | HELD | +0 | 576.9K | +$34M | $56M |
| ATRECA INC | HELD | +0 | 1.40M | −$5M | $4M |
| BFLYBUTTERFLY NETWORK INC | HELD | +0 | 1.01M | −$4M | $7M |
| LUMIRADX LIMITED | HELD | +0 | 5.57M | +$4M | $50M |
| SERASERA PROGNOSTICS INC | HELD | +0 | 779.8K | −$3M | $5M |
| AMYRIS INC | HELD | +0 | 292.4K | −$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CUREVAC N V | COM | 32.65% | $108M | 3.13M |
| 2 | IMCRIMMUNCORE HLDGS PLChistory → | ADS | 16.93% | $56M | 576.9K |
| 3 | LUMIRADX LIMITED | SHS | 15.08% | $50M | 5.57M |
| 4 | BNTXBIONTECH SEhistory → | SPONSORED ADS | 11.62% | $38M | 148.7K |
| 5 | EXSCIENTIA | ADS | 9.53% | $31M | 1.59M |
| 6 | VIRVIR BIOTECHNOLOGY INChistory → | COM | 8.62% | $28M | 677.8K |
| 7 | BFLYBUTTERFLY NETWORK INChistory → | CL A COM | 2.06% | $7M | 1.01M |
| 8 | SERASERA PROGNOSTICS INChistory → | CL A COM | 1.64% | $5M | 779.8K |
| 9 | ATRECA INC | CL A COM | 1.27% | $4M | 1.40M |
| 10 | AMYRIS INC | COM NEW | 0.49% | $2M | 292.4K |
| 11 | ZYUSDZYMERGEN INC | COM | 0.12% | $400,000 | 60.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $44M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $60M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $84M | 8 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $90M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $84M | 9 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $126M | 9 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $113M | 9 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $130M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 10 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $130M | 9 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 11 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $330M | 11 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $342M | 10 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $692M | 8 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $656M | 7 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $438M | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.